TXMD · NASDAQ
TherapeuticsMD (TXMD) Stock Price & Fundamentals
TherapeuticsMD (TXMD) closed at $644.17 on Oct 9, 2026, up 0.42% from the previous close of $641.46.
Share price, past year
1Y +25.13%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $644.17 |
| Sep 30, 2026 | $644.22 |
| Aug 31, 2026 | $621.41 |
| Jul 31, 2026 | $599.36 |
| Jun 30, 2026 | $537.04 |
| May 29, 2026 | $588.54 |
| Apr 30, 2026 | $628.80 |
| Mar 31, 2026 | $589.69 |
| Feb 27, 2026 | $583.36 |
| Jan 30, 2026 | $563.26 |
| Dec 31, 2025 | $516.91 |
| Nov 28, 2025 | $523.94 |
| Oct 31, 2025 | $521.73 |
Key statistics
- Market cap
- $7.46B
- P/E (TTM)
- 8,052.1
- EPS (TTM)
- $0.08
- Revenue (TTM)
- $3.27M
- Net income (TTM)
- −$217.00K
- Shares outstanding
- 11.6M
- Dividend yield
- —
- 52-week range
- $509.23 – $670.62
TherapeuticsMD's market cap is $7.46B, based on a share price of $644.17 and 11.6M shares outstanding as of Jun 30, 2026.
Financials
TherapeuticsMD reported revenue of $3.02M for fiscal 2025, up 71.61% from fiscal 2024.
TherapeuticsMD reported a net loss of $569.00K in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $3.02M | +71.6% | −$569.00K | −18.8% | −$0.05 | — |
| FY2024ended Dec 31, 2024 | $1.76M | +35.3% | −$2.18M | −123.9% | −$0.19 | — |
| FY2023ended Dec 31, 2023 | $1.30M | −98.1% | −$10.28M | −789.4% | −$0.99 | — |
| FY2022ended Dec 31, 2022 | $69.96M | +2,619.1% | $112.00M | 160.1% | $11.96 | — |
| FY2021ended Dec 31, 2021 | $2.57M | −96.0% | −$172.42M | −6,700.9% | −$21.66 | −$142.73M |
| FY2020ended Dec 31, 2020 | $64.87M | +30.7% | −$183.52M | −282.9% | — | −$159.68M |
| FY2019ended Dec 31, 2019 | $49.65M | +208.4% | −$176.15M | −354.8% | — | −$168.17M |
| FY2018ended Dec 31, 2018 | $16.10M | −4.0% | −$132.62M | −823.7% | — | −$107.03M |
| FY2017ended Dec 31, 2017 | $16.78M | −13.3% | −$76.93M | −458.5% | — | −$76.22M |
| FY2016ended Dec 31, 2016 | $19.36M | — | −$89.88M | −464.3% | — | −$69.54M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $869.00K | $155.00K | $0.01 |
| Q1 FY2026ended Mar 31, 2026 | $724.00K | $95.00K | $0.01 |
| Q4 FY2025ended Dec 31, 2025 | $893.00K | −$619.00K | — |
| Q3 FY2025ended Sep 30, 2025 | $784.00K | $152.00K | $0.01 |
| Q2 FY2025ended Jun 30, 2025 | $952.00K | $551.00K | $0.05 |
| Q1 FY2025ended Mar 31, 2025 | $393.00K | −$653.00K | −$0.06 |
| Q4 FY2024ended Dec 31, 2024 | $667.00K | $252.00K | — |
| Q3 FY2024ended Sep 30, 2024 | $547.00K | −$609.00K | −$0.05 |
Company profile
- Name
- TherapeuticsMD, Inc.
- Ticker
- TXMD
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 951 Yamato Road, Suite 220, Boca Raton, FL 33431
- Incorporated in
- NV
- Fiscal year ends
- December
- SEC CIK
- 0000025743
Recent SEC filings
- Aug 11, 2026
- Aug 11, 2026
- May 12, 2026
- May 12, 2026
- Apr 1, 2026
- Mar 30, 2026
- Mar 30, 2026
- Jan 21, 2026
Frequently asked questions
What is TherapeuticsMD's stock price?
TherapeuticsMD (TXMD) closed at $644.17 on Oct 9, 2026, up 0.42% from the previous close of $641.46.
What is TherapeuticsMD's market cap?
TherapeuticsMD's market cap is $7.46B, based on a share price of $644.17 and 11.6M shares outstanding as of Jun 30, 2026.
How much revenue does TherapeuticsMD make?
TherapeuticsMD reported revenue of $3.02M for fiscal 2025, up 71.61% from fiscal 2024.
What is TXMD's P/E ratio?
TherapeuticsMD's price-to-earnings ratio is 8,052.1, based on trailing twelve-month diluted EPS of $0.08.
Does TherapeuticsMD pay a dividend?
TherapeuticsMD's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from TherapeuticsMD, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures